Latest News

A mid-stage study of an experimental GLP-1 drug improved fatty livers without requiring weight loss.

Reporting on the latest research into the skin discoloration disorder Vitiligo, which may lead to new treatments in the future.

EXPERIMENTAL GLP-1 COMBO ?DRUG PROMPTLY IMPROVES FATTY LIVER DAMAGE

Researchers say that combining an experimental GLP-1 weight loss drug with another type was able to produce dramatic improvements in fatty hepatitis in a midstage study. Improvements were visible as soon as 12 weeks following treatment.

The D&D Pharmatech once-weekly combination drug combines its experimental GLP-1 drug, zabopegdutide, with TLY012, designed to induce cell death.

The participants in this trial had fatty liver disease, which was confirmed by biopsy.

Researchers had announced that after 48 weeks, biopsies revealed that patients randomly assigned to receive a new combination drug showed significantly greater reductions in liver fatty tissue and improvement in liver damage than patients who were given a placebo.

Researchers reported in this week's Lancet Gastroenterology and Hepatology that clinically significant improvements in blood tests were evident even after just 12 weeks.

Seulki Lee, D&D's President and CEO, said that many of these benefits were experienced before weight loss was meaningful. This suggests that?zabopegdutide has direct therapeutic effects beyond weight loss on the liver.

Researchers reported that zabopegdutide was effective even among patients who lost less than 5% of their weight in the 12th week.

PIGMENT PRODUCING CELLS CAN REACTIVATE IN WHITE SKI SKIN PATCHES

Researchers in Japan have discovered that pigment-producing cells are still present in white patches of skin due to vitiligo, an autoimmune disorder which causes the skin to lose color.

Researchers reported in Nature Communications that the pigment-producing cell has entered a state where the mature cells have reverted to a primitive form and lost many of their specialized function, including production?of pigment.

In a statement, Dr. Lingli Yang from Osaka University stated that the study revealed a new mechanism for the development of the disease. This could lead to a change in the way we treat it.

The pigment-producing melanocytes are situated on a thin, flexible membrane which provides them with instructions for their continued function.

The melanocytes usually bind to the so-called "basement membrane" via laminin-211. However, in patients with vitiligo, this membrane contains a higher level of laminin-332.

Because their preferred binding protein is no longer available, melanocytes change ?how they attach - and the changes activate pathways that ultimately result in the melanocytes regressing to a non-pigment-producing ?state.

Researchers have used drugs that target these pathways to reactivate melanocytes, pigmentation genes, and reverse many of the features of dormant skin cells.

This was an exciting discovery, because most current treatments focus on suppressing autoimmune reactions and reducing inflammation," said Professor Ichiro Catayama of Osaka University.

It may be possible to find new treatment options, such as reactivating cells or restoring the normal attachment of basement membranes.

(source: Reuters)